IL17A and psoriatic arthritis: Indeed, antibodies neutralizing IL17A have been shown to be powerful therapeutics for human diseases and positive clinical trial data has been reported in psoriasis, psoriatic arthritis, ankylosing spondylitis with now approved drugs such as secukinumab/Cosentyx and ixekizumab/Taltz11–13.